Quantcast

Learn About the Point of Care Diagnostic Testing World Markets

October 9, 2008

Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.

Point of Care Diagnostic Testing World Markets

http://www.reportlinker.com/p096375/Point-of-Care-Diagnostic-Testing-World-Markets.html

The purpose of this TriMark Publications report is to describe the specific market segment of the in vitro diagnostics market called point of care testing (POCT). It examines these clinical measurement devices and their reagents and supplies as utilized in near-patient enviroments like hospitals, clinics and doctor’s offices. An analysis of analytes that are related to the common chemical constituents of blood, plasma or serum at the point of care of the patient is addressed.

Moreover, the study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories.

Additionally, rapid detection of food pathogens and infectious pathogens (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.

 1. Overview 1.1 About this Report 1.2 Scope of the Report 1.3 Objectives 1.4 Methodology 1.5 Executive Summary 2. Overview of Diagnostic Testing Point of Care 2.1 POCT Testing Sites 2.2 POCT Market Structure 2.3 New Directions in Clinical IVD Testing 3. POCT and Rapid Testing Market Analysis: Size, Background Analysis,  Growth, Share and Competitors 3.1 Global POCT Market 3.2 U.S. POCT Market 3.3 European POCT Market  3.3.1 German POCT Diagnostic Market 3.3.2 U.K. POCT Diagnostic Market  3.3.2.1 U.K. POCT Market Statistics 3.3.2.2 U.K. Competitive Analysis 3.3.2.3 U.K. Market Access 3.3.3 French POCT Diagnostic Market 3.3.4 Italian POCT Diagnostic Market 3.3.5 Spanish POCT Diagnostic Market 3.3.6 Scandinavian POCT Diagnostic Market 3.3.7 Swedish POCT Diagnostic Market 3.3.8 Finland POCT Diagnostic Market 3.3.9 Norway POCT Diagnostic Market 3.3.10 Swiss POCT Diagnostic Market 3.3.11 Dutch POCT Diagnostic Market 3.3.12 Belgian POCT Diagnostic Market 3.3.13 Portugal POCT Diagnostic Market 3.3.14 Austria POCT Diagnostic Market 3.3.15 Greek POCT Diagnostic Market 3.3.16 Poland POCT Diagnostic Market 3.3.17 Czech Republic POCT Diagnostic Market 3.3.18 Turkish POCT Diagnostic Market 3.4 Asian POCT Markets  3.4.1 Japanese POCT Diagnostic Market 3.4.2 Indian POCT Diagnostic Market 3.4.3 Chinese POCT Diagnostic Market 3.5 Rest of the World POCT Market  3.5.1 Canada POCT Diagnostic Market 3.5.2 Brazil POCT Diagnostic Market 3.5.3 Australia POCT Diagnostic Market 3.6 Overview of Asian Healthcare Market  3.6.1 Singapore 3.6.2 Malaysia 3.6.3 Thailand 3.6.4 Indonesia 3.6.5 Philippines 3.6.6 South Korea 3.6.7 Taiwan 4. POCT Individual Markets 4.1 Glucose Testing 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors  4.2.1 World Market 4.2.2 U.S. Market 4.2.3 European Market 4.2.3 Alternate Glucose Monitoring Products 4.2.4 HbA1c POCT 4.3 Blood Gas and Electrolytes  4.3.1 Whole Blood Lactate 4.4 Rapid Coagulation Tests  4.4.1 World POCT Coagulation Market 4.4.2 U.S. Coagulation Market 4.4.2 European Coagulation Market 4.5 Rapid Cardiac Markers  4.5.1 U.S. Market 4.5.2 European Market 4.6 Drugs of Abuse Screening Testing  4.6.1 Acetaminophen 4.6.2 Tricyclic Antidepressants (TCAs) 4.6.3 Other Toxic Drugs 4.6.4 Drug Testing Selectivity 4.6.5 Methaqualone and Phencyclidine (PCP) 4.6.6 Tetrahydrocannabinol 4.6.7 Drug Panels by Toxidromes 4.6.8 Alcohol Testing 4.7 Urine Strips 4.8 Pregnancy Tests 4.9 Fecal Occult Blood 4.10 Hemoglobin Testing 4.11 Miscellaneous Rapid Tests  4.11.1 Estriol 4.11.2 Fetal Fibronectin (fFN) 4.11.3 H. pylori 4.11.4 Vaginal pH and Vaginitis 4.11.5 Bladder Cancer 4.11.6 Fetal Status 4.12 Human Immunodeficiency Virus (HIV) 4.13 Cholesterol 4.14 Infectious Disease  4.14.1 C. difficile 4.14.2 Giardia 4.14.3 Salmonella and Campylobacter 4.14.4 Malaria Testing 4.14.5 Influenza Testing 4.14.6 Strep Testing 4.14.7 Chlamydia 4.14.8 Mononucleosis 4.14.9 Rubella 4.14.10 Methicillin-Resistant Staphylococcus aureus (MRSA) 4.14.11 Hepatitis 4.14.12 Gonorrhea 4.14.13 Tuberculosis (TB) 4.14.14 Herpes Simplex Virus Type-2 4.15 Infant Jaundice 4.16 Anthrax 4.15 Rupture of Fetal Membranes (ROM) 4.16 Food Pathogens 4.17 Typhoid 5. POCT: Reagents and Equipment 5.1 Blood Glucose Monitoring  5.1.1 LifeScan 5.1.2 Roche Accu-Chek 5.1.3 Siemens Healthcare Diagnostics 5.1.4 Cholestech (Acquired by Inverness Medical Innovations) 5.1.5 Abbott Diabetes Care 5.1.6 International Technidyne Corporation 5.1.7 HemoCue 5.1.8 Stanbio/GDS Technology 5.1.9 Disetronic Medical Systems 5.1.10 Medtronic MiniMed 5.1.11 Abaxis 5.2 Blood Gas and Electrolytes  5.2.1 Vasamed, Inc. (f/k/a Optical Sensors, Inc.) 5.2.2 Roche Corporation 5.2.3 TechnoMedica 5.2.4 Siemens Healthcare Diagnostics 5.2.5 Instrumentation Laboratory 5.2.6 Nova Biomedical 5.2.7 Radiometer 5.2.8 Abbott Laboratories 5.2.9 Span Diagnostics 5.2.10 Avox Systems 5.2.11 ITC 5.2.12 OPTImedical 5.3 Rapid Coagulation Tests  5.3.1 POC Coagulation Instrument Description  5.3.1.1 Roche Diagnostics Corp. 5.3.1.2 Abbott Laboratories 5.3.1.3 International Technidyne Corp. 5.3.1.4 Medtronic 5.3.1.5 HemoSense 5.3.1.6 Helena Laboratories Point of Care 5.3.1.7 Sienco, Inc. 5.3.1.8 Accumetrics 5.3.2 Connectivity Issues 5.3.3 Cost Benefits 5.3.4 Quality Control Issues 5.3.5 Certification for POC Coagulation Devices 5.4 Rapid Cardiac Markers  5.4.1 Nanogen 5.4.2 Biosite Diagnostics 5.4.3 Roche Diagnostics 5.4.4 Ani Biotech 5.4.5 Response Biomedical Corporation 5.4.6 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare   Diagnostics,Diagnostic Products Corporation, and Dade Behring) 5.4.7 Lab21 Limited 5.4.8 Abbott Laboratories 5.4.9 LifeSign (Princeton BioMediTech Corp) 5.4.10 Mitsubishi Kagaku Iatron 5.5 Rapid Drugs of Abuse  5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations) 5.5.2 Abbott Diagnostics 5.5.3 Roche Diagnostics 5.5.4 BioScan Screening Systems, Inc. 5.5.5 American Bio Medica Corp. 5.5.6 Phamatech, Inc. 5.5.7 Worldwide Medical 5.5.8 OraSure 5.5.9 LifePoint 5.5.10 Avitar, Inc. 5.5.11 Cozart Biosciences 5.5.12 Pathtech 5.5.13 Alfa Scientific Designs, Inc. 5.514 TCPI, Inc. 5.5.15 Roche 5.5.16 Siemens Corporation 5.5.17 Diagnostic Chemical, Ltd. 5.5.18 Quidel 5.5.19 HemoCue (Quest) 5.7 Rapid Pregnancy and Fertility Tests 5.8 Fecal Occult Blood  5.8.1 Helena Laboratories 5.8.2 Biomerica 5.8.3 Beckman Coulter 5.8.4 Worldwide Medical 5.8.5 Aerscher Diagnostics 5.8.6 Enterix 5.8.7 Medix Biochemica 5.9 Hemoglobin Testing 5.9.1 Wampole Laboratories 5.9.2 HemoCue, Inc. 5.9.3 Stanbio/GDS Technology 5.10 Miscellaneous Rapid Tests  5.10.1 Triage C. difficile Panel 5.10.2 Ketoacids 5.10.3 Acetaminophen 5.10.4 Estriol 5.10.5 H. pylori 5.10.6 Vaginal Fluid pH and Vaginitis 5.10.7 Prostate Specific Antigen (PSA) 5.10.8 Bladder Cancer 5.10.9 Other Rapid Cancer Tests 5.10.10 Fetal Status (PROM) 5.10.11 Osteoporosis 5.11 HIV 5.12 Cholesterol  5.12.1 Cholestech (now a brand of Inverness Medical Innovations) 5.12.2 Actimed Laboratories 5.12.3 StatSite Meter 5.12.4 Polymer Technology Systems 5.12.5 PreMD Inc. (f/k/a International Medical Innovations Inc. (IMI)) 5.12.6 Abaxis, Inc. 5.13 Infectious Disease  5.13.1 C. difficile 5.13.2 Giardia 5.13.3 Dengue Fever 5.13.4 Malaria Testing 5.13.5 Rapid Influenza Testing 5.13.6 Streptococcus Testing 5.13.7 Chlamydia 5.13.8 Mononucleosis 5.13.9 Rubella 5.13.10 Staphylococcus aureus and MRSA 5.13.11 Hepatitis 5.13.12 E. coli O157 5.13.13 Gonorrhea Testing 5.13.14 Smallpox 5.13.15 SARS 5.13.16 Rabies 5.13.17 Tuberculosis 5.13.18 Avian Flu 5.13.19 West Nile Virus 5.13.20 Herpes Simplex Virus Type-2 5.14 Infant Jaundice 5.15 Anthrax 5.16 Homeland Defense 5.17 BSE (Mad Cow Disease) 5.18 Tuberculosis 5.19 Typhoid 5.20 Avian flu 5.21 Food Pathogens (Salmonella, Listeria, Campylobacter) 5.22 Ruptured Fetal Membranes (ROM) 6. POCT: Growth Regulators 6.1 Moderators of Growth 6.2 Personnel Acceptance 6.3 Key People for POCT 6.4 Information Management Issues  6.4.1 Elements of Information Management for POCT: Information Processing   Capabilities 6.4.2 Data Mining 6.4.3 Middleware 6.4.4 Web Portals 6.4.5 POCT-1A Standard 6.5 Key Elements for POCT 6.6 POCT and Reimbursement 6.7 Effectiveness of Clinical Outcomes 6.8 Rapid Near-Patient Testing in Hospitals 6.9 Satellite Facilities 6.10 Regionalization of Laboratory Care 6.11 Requirements for POCT 6.12 Locations of Point of Care for Patient Care 6.13 Benefits of POCT 6.14 Cost Elements of POCT 6.15 Necessary Functions in POCT 6.16 TAT for POCT 6.17 Clinical Laboratory Improvement Amendments (CLIA) 6.18 Sexually-Transmitted Diseases in Underdeveloped Countries 7. Business Trends in the Point of Care Sector 7.1 Sector Consolidation 7.2 Diagnostic Testing Growth Trends 7.3 Acquisition, License Agreements, Internal Development and Partnerships 7.4 Product Testing Depth in POCT 7.5 Government Regulation  7.5.1 U.S. Regulation  7.5.1.1 Importing Medical Devices into the U.S. 7.5.1.2 Exporting Medical Devices from the U.S. 7.5.2 U.K. Regulation 7.5.3 E.U. Regulation  7.5.3.1 French Regulation 7.5.4 Japanese Regulation 7.5.5 Korean Regulation 7.6 Increased Market Penetration 7.7 Costs of Doing Business in Europe7.8 Drivers of European Diagnostics Testing 7.9 European Reimbursement Practices 7.10 Cost Containment in Europe 8. Technology Platform Innovations in POCT 8.1 Sensor Systems for Diagnostic Applications 8.2 Glucose Measurements 8.3 Glucose Test Methods 8.4 Cholesterol Testing 8.5 The New Paradigm 8.6 Consolidated Workstations and Modularity 8.7 Automation and Robotics in the Clinical Laboratory 8.8 Laboratory Information Systems (LIS)  8.8.1 NOVIUS Lab 8.9 Biosensor Technology 8.10 Nanogen Third Generaton POC Analyzer 8.11 Quidel MChip 9. Data Management and Connectivity 9.1 Wireless LANs 9.2 Connectivity Platforms 9.2.1 DataLink Data Management System  9.2.2 RALS-Plus 9.2.3 BD.id 9.3 Advantages of POCT Connectivity  9.3.1 Cost Benefit of POCT and IT Connectivity 10. Corporate Profiles 10.1 Abaxis, Inc. 10.2 Abbott Diagnostics 10.3 Accumetrics, Inc. 10.4 Accurex Biomedical, Pvt., Ltd. 10.5 Akers Biosciences 10.6 Alfa Scientific Design, Inc. 10.7 Ambri, Ltd. 10.8 American Bio Medica Corp. 10.9 Ani Biotech 10.10 Apogent Technologies 10.11 Ark Therapeutics 10.12 ARKRAY 10.13 Atlas Genetics 10.14 Atonomics 10.15 Avitar, Inc. 10.16 Avox Systems 10.17 Axis-Shield 10.18 Beckman Coulter 10.19 Binax Corporation 10.20 Biomerica 10.21 BioMerieux Vitek, Inc. 10.22 BioScan Screening Systems, Inc. 10.23 Biosite Diagnostics 10.24 BioStar 10.25 British Biocell Holdings 10.26 Caliper Life Sciences 10.27 Calypte Biomedical 10.28 Chembio Diagnostics 10.29 Cholestech 10.30 Chongqing Sungene Pharmaceutical Co., Ltd. 10.31 CompuCyte Corporation 10.32 Cortech Diagnostics Ltd. (now called Kent International Holdings) 10.33 Cozart Biosciences 10.34 Cygnus Therapeutic Systems 10.35 Cytogen 10.36 Dade Behring 10.37 Daiichi Sankyo Group 10.38 Denka Seiken Co., Ltd. 10.39 Diagnostic Chemicals, Ltd. 10.40 Enterix, Inc. 10.41 Focus Diagnostics, Inc. 10.42 GDS Technology 10.43 GenBio 10.44 Genzyme Diagnostics 10.45 Grant Life Sciences 10.46 Gryphus Diagnostics 10.47 Helena Laboratories 10.48 Hema Diagnostic Systems 10.49 Hemocue, Inc. 10.50 Home Access Health Corp. 10.51 Immunoscience, Inc. 10.52 Instrumentation Laboratory 10.53 International Medical Innovations 10.54 Inverness Medical Innovations 10.55 Johnson & Johnson 10.56 Kyowa Medex Co., Ltd. 10.57 LifeAssays 10.58 LifePoint, Inc. 10.59 LifeScan Corporation 10.60 Lifestream Technologies 10.61 LXN Corp. (Inverness Medical Technologies) 10.62 Matritech 10.63 Medical Services International, Inc. 10.64 MediSense 10.65 Medisys 10.66 Medix Biochemica 10.67 MedMira Laboratories 10.68 Meretek Corporation 10.69 Meridian Bioscience 10.70 MiniMed 10.71 Mitsubishi Chemical USA, Inc. 10.72 Mitsubishi Kagaku Iatron 10.73 Nanogen 10.74 New Horizons Diagnostics 10.75 Nova Biomedical 10.76 OraSure 10.77 Orgenics 10.78 Orion Diagnostica 10.79 PanBio, Ltd. 10.80 Phamatech, Inc. 10.81 PharmaNetics, Inc. 10.82 Polymedco 10.83 Polymer Technology Systems 10.84 Princeton BioMeditech Corporation 10.85 Quest Diagnostics 10.86 Quidel 10.87 Radiometer 10.88 Response Biomedical Corp. 10.89 Roche Diagnostics 10.90 Royal Philips Electronics 10.91 Savyon Diagnostics 10.92 Selfcare, Inc. 10.93 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech) 10.94 Shionogi & Co., Ltd. 10.95 Siemens Corporation 10.96 SpectRx, Inc. 10.97 Spectral Diagnostics 10.98 StatSure Diagnostic Systems 10.99 STC Technologies 10.100 Strategic Diagnostics 10.101 Sun Biomedical Laboratories 10.102 Sybron International Corporation 10.103 Thermo Biostar 10.104 Thoratec/International Technidyne Corp. 10.105 Transmedica 10.106 Trinity Biotech 10.107 Vasamed, Inc. 10.108 Venkateshwara Hatcheries Pvt., Ltd. 10.109 Worldwide Medical Corporation 11. POCT Sector Trends and Forecasts 11.1 Home Care Analysis as Part of Near-Patient Testing 11.2 Non-Traditional Collection for POCT 11.3 New Systems for Critical Care and Near-Patient Testing 11.4 Utility of Near-Patient Testing in Critical Care Settings 11.5 Physician's Office Market 11.6 Information Management Advances 11.7 Test-Ordering Patterns and Demand for POCT 11.8 Demand for Emergency Department Services 11.9 Move Away From Central Laboratory 11.10 Healthcare Cost Controls 11.11 M&A in POCT 11.12 Competition for Services 11.13 Drivers of POCT 11.14 Confluence of New Technology 11.15 Difficulties of Design for POC Products 11.16 European Hospital Structure 11.17 The Biggest New Opportunities in Point of Care Testing 12. Corporate Directory LIST OF FIGURES Figure 3.1: Worldwide Distribution of IVD Testing, 2007 Figure 3.2: Global Point of Care Testing Share of Total In Vitro Diagnostic Testing Market, 2007 Figure 4.1: Number of HbA1c Tests Performed Globally as POCT, 1991-2006 Figure 4.2: Total Spending on Healthcare in the U.S., 1960-2007 Figure 4.3: International Per Capita Healthcare Spending Per Country, 2006 Figure 6.1: Annual Rate of Emergency Room Visits By Primary Expected Source  of Payment: U.S., 2004 INDEX OF TABLES Table 2.1: POC Testing Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2005 Table 3.2: Number of Point of Care Tests in U.S., 2000-2012 Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010 Table 3.4: The Overall In Vitro Diagnostic Testing Market Worldwide in 2007 Table 3.5: Worldwide Distribution of IVD Testing in 2007 Table 3.6: Top Twelve Country IVD Testing Markets, 2007 Table 3.7: Thirteen Largest Diagnostic Companies Worldwide, 2007 Table 3.8: Global Point of Care Revenues, 2005-2012 Table 3.9: Worldwide POCT Market Size by Geographic Location, 2005-2012 Table 3.10: Worldwide Distribution of POCT, 2007 Table 3.11: Worldwide POCT by Performance Location, 2007 Table 3.12: Worldwide Clinical Diagnostic POCT and Rapid Test Market  Segments, 2007 Table 3.13: Largest POCT Diagnostic Companies Worldwide, 2007 Table 3.14: U.S. Clinical Laboratory Testing Market, 2003-2012 Table 3.15: U.S. Clinical Laboratory Diagnostic Test Market Segments by  Location of Analysis, 2007 Table 3.16: U.S. POCT Market, 2000-2012 Table 3.17: U.S. POCT by Performance Location, 2007 Table 3.18: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments,  2007 Table 3.19: European Clinical Laboratory Testing IVD Reagents and  Instruments Market ($), 2000-2012 Table 3.20: European Clinical Laboratory Testing IVD Reagents and  Instruments Market, 2000-2012 Table 3.21: European Clinical Laboratory Testing Diagnostics by Country  Market stimates, 2007 Table 3.22: European Rapid Point of Care Testing by Country Market  Estimates,2007 Table 3.23: Regional Comparison of Healthcare Spending for IVD for  Eastern Europe Table 3.24: European POCT Market, 2005-2012 Table 3.25: Top Twelve Country IVD and POC Testing Markets, 2007 Table 3.26: German Clinical Laboratory Testing Diagnostics Products  Market Sales, 2003-2012 Table 3.27: German POCT Diagnostics Products Market Sales, 2003-2012 Table 3.28: German Clinical Diagnostic Rapid Test Market Segments, 2007 Table 3.29: U.K. Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.30: U.K. POCT Diagnostics Products Market Sales, 2006-2012 Table 3.31: U.K. Clinical Diagnostic Rapid Test Market Segments, 2007 Table 3.32: Major U.K. IVD Manufacturers Table 3.33: U.S. IVD Manufacturers Doing Business in the U.K. Table 3.34: Other European Companies that Manufacture IVD Products in  the U.K. Table 3.35: French Clinical IVD Testing Diagnostics Products Market  Sales, 2003-2012 Table 3.36: French POCT Diagnostics Products Market Sales, 2005-2012 Table 3.37: French Clinical Diagnostic Rapid Test Market Segments, 2007 Table 3.38: Italian Laboratory Diagnostics Products Market Sales, 2003-2012 Table 3.39: Italian POCT Diagnostics Products Market Sales, 2005-2012 Table 3.40: Italian Clinical Diagnostic Rapid Test Market Segments, 2007 Table 3.41: Spanish Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.42: Spanish Clinical Diagnostic Rapid Test Market Segments, 2007 Table 3.43: Spanish POCT Diagnostics Products Market Sales, 2005-2012 Table 3.44: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012 Table 3.45: Swedish Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.46: Swedish POCT Diagnostics Products Market Sales, 2005-2012 Table 3.47: Finnish Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.48: Finnish POCT Diagnostics Products Market Sales, 2005-2012 Table 3.49: Norwegian Clinical Laboratory Diagnostics Products Market   Sales,2003-2012 Table 3.50: Norwegian POCT Diagnostics Products Market Sales, 2005-2012 Table 3.51: Swiss Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.52: Swiss POCT Diagnostics Products Market Sales, 2005-2012 Table 3.53: Dutch Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.54: Dutch POCT Diagnostics Products Market Sales, 2005-2012 Table 3.55: Belgium Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.56: Belgium POCT Diagnostics Products Market Sales, 2005-2012 Table 3.57: Portuguese Clinical Laboratory Diagnostics Products Market  Sales, 2003-2012 Table 3.58: Portuguese POCT Diagnostics Products Market Sales, 2005-2012 Table 3.59: Austrian Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.60: Austrian POCT Diagnostics Products Market Sales, 2005-2012 Table 3.61: Greek Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.62: Greek POCT Diagnostics Products Market Sales, 2005-2012 Table 3.63: Polish Clinical Laboratory Diagnostics Products Market Sales,  2003-2012 Table 3.64: Polish POCT Diagnostics Products Market Sales, 2005-2012 Table 3.65: Czech Clinical Laboratory Diagnostics Products Market Sales,  2004-2012 Table 3.66: Czech POCT Diagnostics Products Market Sales, 2005-2012 Table 3.67: Turkish POCT Market, 2000-2012 Table 3.68: Japan POCT Market, 2000-2012 Table 3.69: Japanese Population and Aging Demographics Forecast, 2000-2050 Table 3.70: Indian IVD Market for Instruments and Reagents, 2004-2012Table 3.71: Number of Automated Clinical Labs in India, 2004-2012 Table 3.72: Indian IVD Market, 2007 Table 3.73: Indian POCT Diagnostics Products Market Sales, 2000-2008 Table 3.74: Chinese IVD Market, 2006-2012 Table 3.75: Number of Automated Clinical Labs in China, 2004-2012 Table 3.76: Chinese IVD Market, 2007 Table 3.77: Chinese POCT Diagnostics Products Market Sales, 2000-2012 Table 3.78: The Rest of the World POCT Market, 2000-2012 Table 3.79: Canadian POCT Market, 2000-2012 Table 3.80: Brazilian POCT Market, 2000-2012 Table 3.81: Australian POCT Market, 2000-2012 Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers Table 4.2: The Global Population of Persons with Diabetes, 1995 and 2025 Table 4.3: The Glucose Testing Market for POCT Worldwide, 2001-2012 Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012 Table 4.5: Manufacturer Market Share U.S. POCT Market, 2007 Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment Table 4.7: The HbA1c Testing Market for POCT Worldwide, 2006-2012 Table 4.8: The Critical Care Blood Gas Testing Market for POCT Worldwide,  2006-2012 Table 4.9: The Blood Gas and Electrolyte Market for POCT in the U.S.,  2001-2012 Table 4.10: Location Market Share of Critical Care Blood Gas Testing Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes  Market, 2007 Table 4.12: The Coagulation Testing Market for POCT Worldwide, 2006-2012 Table 4.13: The Hand-held Coagulation Testing Market for POCT Worldwide,  2006-2012 Table 4.14: The Coagulation Market for POCT in the U.S., 2001-2012 Table 4.15: The POC Prothrombin Market for POCT in the U.S., 2000-2007 Table 4.16: The Cardiac Marker Market for POCT in the U.S., 2001-2012 Table 4.17: The Cardiac Marker Market for POCT Worldwide, 2001-2012 Table 4.18: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2007 Table 4.19: The Cardiac Marker Market for POCT in Europe, 2001-2011 Table 4.20: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012 Table 4.21: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012 Table 4.22: Drug Testing Needs Tier 1 for Rapid Serum Point of Care Testing  in the Emergency Department Table 4.23: Stat Urine Testing Drug Recommendations Table 4.24: Device Specifications for POCT Breath Alcohol Analysis Table 4.25: Global Point of Care Urine Test Strip Testing Market, 2001-2007 Table 4.26: Global Point of Care Urine Test Strip POCT Testing Market,  2006-2012 Table 4.27: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011 Table 4.28: U.S. Point of Care Urine Test Strip Testing Market Share Table 4.29: Medicare Fee Schedule for Urine Chemistry Testing Table 4.30: Pregnancy Testing Market for POCT Worldwide, 2006-2012 Table 4.31: U.S. Point of Care Pregnancy Testing Market, 2001-2012 Table 4.32: International Point of Care Pregnancy Testing Markets, 2001-2007 Table 4.33: U.S. Market Share for Rapid Point of Care Pregnancy Tests Table 4.34: Hemoglobin Testing Market for POCT Worldwide, 2006-2012 Table 4.35: Worldwide POCT Market for HIV, 2001-2012 Table 4.36: U.S. POCT Market for HIV, 2001-2012 Table 4.37: Countries with the Highest Prevalence of HIV/AIDS Table 4.38: FDA-Approved Rapid HIV Antibody Screening Tests Table 4.39: OraSure OraQuick Rapid HIV Test Revenues, 2005 Table 4.40: The Cholesterol Testing Market for POCT Worldwide, 2006-2012 Table 4.41: The Infectious Disease Testing Market for POCT Worldwide,  2006-2012 Table 4.42: Salmonella Testing Market, 2002-2007 Table 4.43: Worldwide Point of Care Influenza Testing Market, 2002-2007 Table 4.44: U.S. Point of Care Influenza Testing Market, 2002-2007 Table 4.45: International Point of Care Influenza Testing Markets,  2002-2007 Table 4.46: U.S. Market for Rapid Point of Care Influenza Tests, 2007 Table 4.47: Worldwide Point of Care Strep A Testing Market, 2002-2007 Table 4.48: U.S. Point of Care Strep A Testing Market, 2002-2007 Table 4.49: International Point of Care Strep A Testing Markets, 2002-2007 Table 4.50: U.S. Market for Rapid Point of Care for Group A Strep Tests Table 4.51: Global Market for Chlamydia Diagnostic Testing, 2000-2009 Table 4.52: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009 Table 4.54: Global Market for Gonorrhea Diagnostic Testing, 2000-2009 Table 4.55: Global Market for TB Diagnostic Testing, 2000-2008 Table 4.56: U.S. Anthrax Test Market Table 5.1: Drug Test Sensitivity Cut-Off Levels Established as Standard by  NIDA, WHO and SAMHSA for Drugs of Abuse Table 5.2: Major Competitors in the Drugs of Abuse Testing Market Segment Table 5.3: Major Competitors in the Drugs of Abuse Oral Testing Market  Segment Table 5.4: Major Competitors in the Drugs of Abuse Urine Testing Market  Segment Table 5.5: Major Competitors in the Drugs of Abuse Saliva Testing Market  Segment Table 5.6 Siemens Urinalysis Near-patient Devices Table 5.7: ColoCARE Fecal Occult Blood Test Table 5.8: Type of Hepatitis Test: Lateral Flow Table 5.9: Flow-Through Table 5.10: Agglutination Table 5.11: Immunoblot Table 5.12: AmniSure Table 6.1: Access Points Table 6.2: Desktop Adapters-One Computer Table 6.3: Desktop Adapters-Four Computers Table 6.4: PCMCIA Adapters Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements Table 6.8: POCT in Three Hospitals. Cost Analysis with Labor Included Table 6.9: Cost Analysis for Glucose Testing: POCT vs. Central Lab Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs Table 7.1 Key Changes in IVD Business Structure Table 7.2 Business Trends in Point of Care Testing Table 7.3 Key Players Bring Business Developments to Point of Care  DiagnosticTesting Table 8.1: Normal Glucose Values-Fasting State Table 9.1: Applications for Wireless LAN Technology Table 9.2: Customized Reports Must Support CAP and JCAHO Requirements Table 9.3 RALS-Plus Point of Care Market Share Table 9.4: Applications of RALS Connectivity with POCT Devices Table 10.1: Abaxis Blood Analysis Diagnostic Tests Table 10.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers Table 10.3: Products Marketed by Abbott in the Diagnostic Market Table 10.4: Quidel Product Sales Distribution and Sales, 2007 Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT Table 11.2: Test Menu and TAT for ED Table 11.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the  ED Table 11.4: Key Areas and Metrics That Hospitals Measure To Assess  Efficiency of ED Table 11.5: Estimates of Patient Costs by DRG 

To order this report:

Point of Care Diagnostic Testing World Markets

http://www.reportlinker.com/p096375/Point-of-Care-Diagnostic-Testing-World-Markets.html

More market research reports here!

 Contacts: Reportlinker.com Nicolas US: (805) 652-2626 or Intl: +1-805-652-2626 Email: nbo@reportlinker.com

SOURCE: Reportlinker.com




comments powered by Disqus